---
title: "Oncology Institute - CW22 | 10-Q: FY2025 Q2 Revenue: USD 119.8 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252921348.md"
datetime: "2025-08-13T21:14:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252921348.md)
  - [en](https://longbridge.com/en/news/252921348.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252921348.md)
---

# Oncology Institute - CW22 | 10-Q: FY2025 Q2 Revenue: USD 119.8 M

Revenue: As of FY2025 Q2, the actual value is USD 119.8 M.

EPS: As of FY2025 Q2, the actual value is USD -0.15.

### Patient Services Segment

-   **Revenue**: $55,891 for the three months ended June 30, 2025, and $108,959 for the six months ended June 30, 2025, representing a 6.5% and 3.9% increase, respectively, compared to the same periods in 2024.
-   **Direct Costs**: $51,150 for the three months ended June 30, 2025, and $98,230 for the six months ended June 30, 2025, representing a 9.9% and 2.3% increase, respectively, compared to the same periods in 2024.
-   **Operating Income**: $3,256 for the three months ended June 30, 2025, and $7,770 for the six months ended June 30, 2025.

### Dispensary Segment

-   **Revenue**: $62,573 for the three months ended June 30, 2025, and $111,866 for the six months ended June 30, 2025, representing a 40.8% and 33.0% increase, respectively, compared to the same periods in 2024.
-   **Direct Costs**: $51,086 for the three months ended June 30, 2025, and $90,949 for the six months ended June 30, 2025, representing a 31.7% and 27.0% increase, respectively, compared to the same periods in 2024.
-   **Operating Income**: $11,483 for the three months ended June 30, 2025, and $20,911 for the six months ended June 30, 2025.

### Clinical Trials & Other Segment

-   **Revenue**: $1,338 for the three months ended June 30, 2025, and $3,383 for the six months ended June 30, 2025, representing a decrease of 20.2% and 19.7%, respectively, compared to the same periods in 2024.
-   **Direct Costs**: $65 for the three months ended June 30, 2025, and $279 for the six months ended June 30, 2025, representing a decrease of 71.6% and 55.0%, respectively, compared to the same periods in 2024.
-   **Operating Income**: $1,218 for the three months ended June 30, 2025, and $2,962 for the six months ended June 30, 2025.

### Outlook

The company has implemented initiatives to reduce costs and manage working capital effectively, resulting in a 3.5% reduction in SG&A expenses compared to the prior year same quarter. The company expects these efforts to continue improving cash flow and operational efficiency.

### Related Stocks

- [TOIIW.US](https://longbridge.com/en/quote/TOIIW.US.md)
- [STLNW.US](https://longbridge.com/en/quote/STLNW.US.md)